SCHEMBL4874534

SCHEMBL4874534

CN1CCC(c2ccc(S)cc2Cl)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ QDPR P09417 2/20 0.39
▸ HTR1D P28221 2/20 0.38
▸ HTR1B P28222 2/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ THPO P40225 1/20 0.38
▸ DRD4 P21917 1/20 0.38
▸ OPRL1 P41146 2/20 0.37
▸ LSS P48449 1/20 0.37
▸ POLB P06746 1/20 0.36
▸ MAPK11 Q15759 1/20 0.36
▸ MAPK14 Q16539 1/20 0.36
▸ HTR6 P50406 1/20 0.35
▸ HTR1F P30939 2/20 0.35
▸ SLC6A2 P23975 1/20 0.35
▸ SLC6A4 P31645 1/20 0.35
▸ SLC6A3 Q01959 1/20 0.35
▸ KCNH2 Q12809 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6615041 0.90 SLC6A2 (0.42) HTR1DHTR1BHTR6SLC6A2SLC6A4
SCHEMBL4876589 0.90 SLC6A2 (0.42) HTR1DHTR1BHTR6SLC6A2SLC6A4
SCHEMBL4869830 0.90 SLC6A2 (0.42) HTR1DHTR1BHTR6SLC6A2SLC6A4
SCHEMBL4969638 0.83 OPRL1 (0.47) HTR1DDRD4OPRL1LSSPOLB
SCHEMBL14924437 0.81 SLC6A2 (0.42) QDPRHTR1DHTR1BCYP1A2CYP3A4
SCHEMBL12073521 0.80 HTR1D (0.55) QDPRHTR1DHTR1BCYP1A2CYP3A4
SCHEMBL4972924 0.80 OPRL1 (0.51) OPRL1MAPK14HTR1FSLC6A4
SCHEMBL14924095 0.78 HTR2A (0.43) QDPRHTR1DHTR1BCYP1A2CYP3A4
SCHEMBL10078312 0.75 HTR1A (0.47) HTR6
SCHEMBL4976022 0.75 OPRL1 (0.47) OPRL1MAPK14HTR1FSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7408067-B2 Aza-cyclic compounds as modulators of acetylcholine receptors MERCK + CO., INC. (US) 2008-08-05 — — US disclosed
US-20050070520-A1 Aza-cyclic compounds as modulators of acetylcholine receptors MERCK SHARP & DOHME CORP. 2005-03-31 — — US disclosed
EP-1467986-A1 AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS ELI LILLY AND COMPANY (US) 2004-10-20 — — EP disclosed
WO-2003062224-A1 AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS ELI LILLY AND COMPANY (US) 2003-07-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070520-A1 Aza-cyclic compounds as modulators of acetylcholine receptors CHRNG, CHRNA4, CHRNB4 QDPR 82/4885HTR1D 548/4885HTR1B 244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback